We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Horizon to Re-evaluate Relationship With Express Scripts

Horizon to Re-evaluate Relationship With Express Scripts

November 17, 2015

Horizon Pharma CEO Timothy Walbert says the company will re-evaluate its relationship with Express Scripts after the pharmacy benefits manager filed suit against the drugmaker and terminated one of its drug dispensers, Linden Care.

Express Scripts announced it would remove Linden Care from its network after alleging the company did not fulfill key components of the pharmacy network agreements in dispensing Horizon’s drugs. It also said it is evaluating several other pharmacies that appear to be predominantly dispensing Horizon prescription drugs.

The PBM said it is reviewing and evaluating “all similar captive pharmacy arrangements that we know of and will work to identify others. By captive pharmacies, we mean those pharmacies that derive the vast majority of their prescription volume from one manufacturer and/or one product.”

Walbert denies that Linden Care is a “captive pharmacy,” beholden to Horizon. He adds that less than 5 percent of net sales are prescriptions filled by Linden Care and processed by Express Scripts.

Walbert says that Express Scripts has “significant control over prescriptions that flow to specialties pharmacies” and that it also operates its own mail-order pharmacy, thus creating a “clear conflict of interest.”

“Our philosophy of ensuring that patients get the medicine their doctors prescribe is threatening Express Scripts' profiteering and exposing what we believe is a lack of care for patients and respect for physicians,” Walbert says in a statement.

The war of words between the two companies came the same week Valeant Pharmaceuticals executives tried to allay nervous investors following weeks of scandal about its pricing practices and relationship with a specialty pharmacy.

Express Scripts also filed a complaint in a Delaware court against Horizon seeking to recover roughly $140 million, contending it refused to honor contractual obligations under a manufacturer rebate agreement.

Horizon says it terminated the rebate agreement about a year ago, contending Express Scripts didn’t live up to its contractual obligations and failed to fix the breaches when notified by Horizon. The present lawsuit relates to that terminated agreement, Walbert says, noting that the PBM is pursuing damages related to prescriptions occurring after the contract was terminated.

“At best Express Scripts is being reckless in its allegations, and at worse it is intentionally attempting to mislead investors,” Walbert says.

Pharmaceuticals Commercial Operations

Upcoming Events

  • 08Sep

    Organizing Data and Document Archives: Finding a Needle in a Haystack for FDA Inspections

  • 15Sep

    Califf’s Post-PDUFA, Post-COVID FDA Agenda: Key Developments, Insights and Analysis

  • 20Sep

    Building a World-Class Pharmaceutical Advertising and Promotion Review Program

  • 21Sep

    The FDA’s Focus on Clinical Data Integrity Throughout Product Development and Approval

  • 22Sep

    FDA’s New Quality Management System Regulation: What the Proposed Harmonization with ISO 13485 Means for Devicemakers

  • 11Oct

    1st Annual Quality Management vSummit

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • Thermo Fisher Scientific Gets FDA Premarket Approval for Companion Diagnostic

  • MHRA Grants Conditional Authorization to Moderna’s Bivalent COVID-19 Booster Vaccine

  • Organogenesis Gets 510(k) Clearance to Expand PuraPly Portfolio

  • FDA Grants Priority Review to sNDA for Lynparza

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing